Myriad Genetics expanded the availability of its ultrasensitive Precise MRD test beyond a breast-cancer early access program. The company is broadening indications to colorectal and renal cancers and widening access beyond approximately 20 physicians at large academic centers and smaller community oncology settings. In breast cancer data published in Future Oncology from the multicenter MONITOR-Breast study, Myriad reported that ctDNA monitoring during neoadjuvant therapy predicted pathological complete response with 100% specificity. Patients who remained ctDNA-positive after therapy were 47 times more likely to remain positive post-surgery, supporting MRD risk stratification. Myriad’s tumor-informed whole-genome sequencing-based approach tracks up to 1,000 variants per patient, aiming for ultrasensitive detection in low ctDNA settings. The next milestone is building the evidence base to support clinical adoption across the expanded indications.